DeepCure

DeepCure is a private, preclinical-stage biotech applying a proprietary AI/ML and physics-integrated platform to drug difficult targets in immunology. The company has identified its first two development candidates: DC-9476, an oral BRD4-BD2 inhibitor for rheumatoid arthritis and related conditions, and DC-15442, an oral STAT6 inhibitor for asthma and atopic dermatitis, both in IND-enabling studies. With a leadership team combining deep AI expertise from MIT with seasoned drug development experience from major pharma, DeepCure aims to create a new class of oral therapies for diseases dominated by injectable biologics.

Integrated platform combining advanced AI/ML, physics-based computational chemistry tools, and laboratory automation for the discovery of novel small molecules against challenging targets.

DeepCure competes in the crowded AI-drug discovery sector against companies like Recursion, Exscientia, and Atomwise, as well as in the specific immunology space against large pharma and biotechs developing both biologics and oral small molecules. Its key differentiator is the deep integration of physics-based tools with AI and a focused pipeline on validated but challenging immunology targets.